Who
Mutya Harsch
Chief Legal Officer and Gc
Company insider
Files Form 4 as: Chief Legal Officer and Gc, VYNE Therapeutics; Director, Satsuma Pharmaceuticals; CLO and General Counsel, Foamix Pharmaceuticals.
In numbers
- Trades disclosed
- 77
- Buys
- 1
- Sells
- 2
- Bought
- $25K
- Sold
- $11K
- Companies
- 3
- Companies where not an officer
- 1
- First trade
- 27 Feb 2018
- Last trade
- 23 Jul 2026
- Last filed
- 24 Jul 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 23 Jul 2026filed 24 Jul 2026 | VYNE TherapeuticsBiotechnology | SEC FORM 4 Code F | $20K22,516 at $0.8976 | filing |
| 23 Jul 2026filed 24 Jul 2026 | VYNE TherapeuticsBiotechnology | SEC FORM 4 Code F | $20K22,516 at $0.90 | filing |
| 30 Jun 2026filed 2 Jul 2026 | VYNE TherapeuticsBiotechnology | SEC FORM 4 Code F | $2,2543,464 at $0.6507 | filing |
| 30 Jun 2026filed 2 Jul 2026 | VYNE TherapeuticsBiotechnology | SEC FORM 4 Code F | $2,2523,464 at $0.65 | filing |
| 31 Mar 2026filed 2 Apr 2026 | VYNE TherapeuticsBiotechnology | SEC FORM 4 Code F | $2,3944,007 at $0.5975 | filing |
| 31 Mar 2026filed 2 Apr 2026 | VYNE TherapeuticsBiotechnology | SEC FORM 4 Code F | $2,4044,007 at $0.60 | filing |
| 31 Dec 2025filed 5 Jan 2026 | VYNE TherapeuticsBiotechnology | SEC FORM 4 Code F | $2,0763,579 at $0.5801 | filing |
| 31 Dec 2025filed 5 Jan 2026 | VYNE TherapeuticsBiotechnology | SEC FORM 4 Code F | $2,0763,579 at $0.58 | filing |
| 30 Sep 2025filed 2 Oct 2025 | VYNE TherapeuticsBiotechnology | SEC FORM 4 Code F | $1,2183,581 at $0.34 | filing |
| 30 Jun 2025filed 2 Jul 2025 | VYNE TherapeuticsBiotechnology | SEC FORM 4 Code F | $5,9093,581 at $1.65 | filing |
| 2 Jun 2025filed 3 Jun 2025 | VYNE TherapeuticsBiotechnology | SEC FORM 4 Code A | $9271,145 at $0.81 | filing |
| 31 Mar 2025filed 2 Apr 2025 | VYNE TherapeuticsBiotechnology | SEC FORM 4 Code F | $14K8,828 at $1.58 | filing |
| 21 Jan 2025filed 23 Jan 2025 | VYNE Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —230,000 at $0.00 | filing |
| 31 Dec 2024filed 2 Jan 2025 | VYNE TherapeuticsBiotechnology | SEC FORM 4 Code F | $16K4,697 at $3.35 | filing |
| 30 Sep 2024filed 2 Oct 2024 | VYNE TherapeuticsBiotechnology | SEC FORM 4 Code F | $197105 at $1.88 | filing |
| 1 Jul 2024filed 3 Jul 2024 | VYNE TherapeuticsBiotechnology | SEC FORM 4 Code F | $275143 at $1.92 | filing |
| 1 Apr 2024filed 3 Apr 2024 | VYNE TherapeuticsBiotechnology | SEC FORM 4 Code F | $496161 at $3.08 | filing |
| 2 Jan 2024filed 3 Jan 2024 | VYNE TherapeuticsBiotechnology | SEC FORM 4 Code F | $367161 at $2.28 | filing |
| 1 Jan 2024filed 3 Jan 2024 | VYNE Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —62,500 at $0.00 | filing |
| 1 Jan 2024filed 3 Jan 2024 | VYNE TherapeuticsBiotechnology | SEC FORM 4 Code A | —62,500 at $0.00 | filing |
News
No headline names them, or the companies they trade most, lately.